Table 1.

Characteristics of Patients at Baseline (ITT)

	Rivaroxaban 10 mg (n = 4,909)	Placebo (n = 4,913)
Male	55.3	55.7
Mean age, yrs	67.8	67.7
White race	96.3	96.7
Mean BMI, kg/m2	29.5	29.3
Reason for hospitalization
Heart failure	37.4	37.0
Respiratory insufficiency or exacerbation of chronic obstructive pulmonary disease	27.6	28.0
Ischemic stroke	15.5	15.7
Infectious disease	17.9	17.7
Inflammatory disease	1.5	1.7
Mean duration of index hospitalization, days	6.7	6.7
D-dimer >2× upper limit of normal during the index hospitalization	68.7	68.7
Mean baseline CrCl	87.9	87.8
Baseline aspirin	51.9	49.1
Current or former smoker	48.2	48.3
Baseline statin	41.9	41.4
Baseline U.S.-approved thromboprophylaxis	71.2	71.5
History of hypertension	78.2	78.8
History of diabetes	29.5	27.9
History of heart failure	47.9	47.5
History of coronary artery disease	32.1	31.1
History of hyperlipidemia	20.5	19.6
History of cancer	8.0	8.7
IMPROVE VTE risk factor score
2	35.5	36.0
3	29.3	27.4
≥4	35.1	36.4

Values are % or mean (where indicated). Note: intention-to-treat (ITT): all randomized patients who had valid signed informed consent. U.S.-approved thromboprophylaxis includes enoxaparin, dalteparin, and heparin. Patients who have both U.S.-approved and other baseline use of thromboprophylaxis are included in the U.S.-approved thromboprophylaxis category.

BMI = body mass index; CrCl = creatine clearance; IMPROVE VTE = International Medical Prevention Registry on Venous Thromboembolism venous thromboembolism model.